Date: 14th November, 2025

To,
BSE Limited
Corporate Relation Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Script Code - 538874

Sub: Outcome of Board Meeting held on Friday, 14th November, 2025

Dear Sir / Madam,

We would like to inform you that the meeting of the Board of Directors of Nexus Surgical and Medicare Limited was held on Friday, 14th November, 2025 at 03:30 p.m. at the Registered Office of the Company situated at Gala No. 4, Saarthak, Building No. 1, Square Industrial Park, Tungarphata, Vasai (East), Palghar - 401 208 and transacted the following business:

1. The Board of Directors of the Company has approved the unaudited quarterly financial results of the Company for the quarter and half year ended 30th September, 2025. A copy of the same alongwith Limited Review Report on the said results is enclosed herewith.

The meeting commenced at 03:30 p.m. and concluded at 04:15 p.m.

Kindly take the same on your records.

Thanking you. Yours faithfully, For Nexus Surgical and Medicare Limited

Ram Swaroop Joshi DIN: 07184085 Managing Director

Encl: as above

Nexus Surgical and Medicare Limited

Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2025

(Rs. in lakh, except equity per share data)

		Quarter ended o	n	Half Year Ended on		Year ended
	Sep 30, 2025	June 30, 2025	Sep 30, 2024	Sep 30, 2025	Sep 30, 2024	Mar 31, 2025
Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income:					 	
Sales and Services	116.58	172.52	99.49	289.11	275.52	572.09
Other Income		-	-	-	-	0.73
Total Income	116.58	172.52	99.49	289.11	275.52	572.83
Expenses						
Purchase of stock-in-trade	42.87	75.47	62.98	118.34	84.09	189.77
Change in inventories of stock-in-trade	17.31	(17.18)	(26.28)	0.13	8.14	(2.66)
Employee benefits expense	11.58	11.32	4.87	22.91	10.38	40.67
Depreciation and amortization expense	0.10	0.10	0.10	0.20	0.20	0.39
Other expense	21.52	82.43	30.31	103.95	133.20	277.86
Total Expenses	93.38	152.15	71.98	245.52	236.02	506.04
Profit/(loss) before Exceptional Item and Tax	23.21	20.38	27.51	43.58	39.50	66.79
Exceptional Item Income/(Loss)	-	-	-	-	-	-
Profit/(loss) before Tax	23.21	20.38	27.51	43.58	39.50	66.79
Current Tax	5.84	5.13	6.94	10.97	9.94	17.00
Tax for earlier years	-	-	-	-	-	(0.05)
Deferred Tax			-	-	-	0.10
Tax expenses	5.84	5.13	6.94	10.97	9.94	17.05
Profit/(loss) for the period	17.37	15.25	20.56	32.61	29.56	49.74
Other comprehensive income (OCI), net of income tax						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Items that will be reclassified to profit or loss	-	-	-	-	-	-
Total other comprehensive income, net of income tax	-	-	-	-	-	-
Total other comprehensive income for the period	17.37	15.25	20.56	32.61	29.56	49.74
Detal on Footh Chara Control (Footh character & De 40	F 47.40	547.40	F 47 40	F 47 40	F 47 10	547.40
Paid-up Equity Share Capital (Equity shares of Rs. 10 each)	547.19	547.19	547.19	547.19	547.19	547.19
Reserve excluding revaluation reserves						(440.83)
Basic and Diluted Earning Per Share (not annualized)	0.32	0.28	0.38	0.60	0.54	0.91

Notes:

- 1 The above Unaudited Financial result have been reviewed and recommended by the audit committee and have been approved by the Board of Directors at their meeting held on November 14, 2025. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 2 The aforesaid unaudited financial results for the quarter and half year ended September 30, 2025 has been prepared in accordance with Companies (Indian Accounting Standard) Rule, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of SEBI (Listing Obligation and disclosure Requirements) Regulations, 2015, as amended.
- 3 The Company has only one operating segment, namely Trading, & is governed by similar set of risk and return hence disclosure requirements as per Ind AS 108 are not applicable.
- 4 Previous period figures have been restated or regrouped or rearranged wherever necessary, to make them comparable.
- 5 The company has not received any shareholder / investors complaints during the quarter ended September 30, 2025.

For and on behalf of Board of Directors of Nexus Surgical and Medicare Limited

Ram Swaroop Joshi Managing Director DIN: 07184085

Vasai

November 14, 2025

Nexus Surgical and Medicare Limited

Note 6: Statement of Assets and Liabilities

		(Rs. in lakhs)
	As at	As at
	Sep 30, 2025	Mar 31, 2025
Particulars	(Unaudited)	(Audited)
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	2.20	2.40
(b) Deferred Tax Assets (Net)	0.71	0.71
Current assets		
(a) Inventories	42.77	42.90
(b) Financial Assets:		
(i) Trade receivables	121.98	133.77
(ii) Cash and cash equivalents	16.66	33.13
(iii) Loans and Advances	-	-
(iv) Other Financial Assets	4.25	4.25
(c) Other current Assets	44.08	10.30
Total Assets	232.65	227.45
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	547.19	547.19
(b) Other Equity	(408.21)	(440.83)
LIABILITIES		
Current liabilities		
(a) Financial Liabilities		
(i) Trade payables	81.60	117.76
(b) Other current liabilities	12.08	3.33
Total Equity and Liabilities	232.65	227.45

Nexus Surgical and Medicare Limited

Note 7: Statement of Cash Flow

		(Rs. in lakhs)
	As at	As at
Particulars	Sep 30, 2025	Sep 30, 2024
Profit before tax	43.58	39.50
Adjustment to reconcile net profit to net cash provided by operating activities		
Depreciation expenses	0.20	0.20
	43.79	39.70
Change in assets & liabilities		
Trade receivables	11.79	(45.18)
Inventories	0.13	8.14
Other Assets	(33.78)	12.74
Trade payables	(36.16)	(10.50)
Other financial & other liabilities	8.75	4.84
Cash generated from operating activities	(5.50)	9.74
Income Tax Paid	10.97	9.94
Net Cash generated from operating activities	(16.46)	(0.20)
Cash flow from investing activities		
Loans & advances	-	(15.00)
Assets Purchase	-	(0.71)
	-	(15.71)
Cash flow from financing activities	-	-
Net cash generated	(16.46)	(15.91)
Cash & cash equivalents at the beginning of the year	33.13	23.41
Cash & cash equivalents at the end of the year	16.66	7.51
Reconciliation of cash and cash equivalents as per the cash flow statement	į	
Cash and cash equivalents as per above comprise of the following		
cash and cash equivalents as per above comprise of the following		
Cash and cash equivalents	16.66	7.51
Balances per statement of cash flows	16.66	7.51

CA SATYA PRAKASH NATANI DISA(ICAI),FAFD CA SANGEETA PAREKH

CA SURESHKUMAR YADAV

CA ARCHANA JAIN

CA ANU OSWAL

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025.

To
The Board of Directors
Nexus Surgical and Medicare Limited

We have reviewed the accompanying Statement of unaudited standalone financial results of Nexus Surgical and Medicare Limited, for the quarter and half year ended September 30, 2025, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that We plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of

Satya Prakash Natani & Co. Chartered Accountants

Firm's Registration No.: 115438W

Satya Prakash Natani Partner

Membership No.: 048091

Mumbai

November 14, 2025

UDIN: 25048091BMKQST5013

Office: 505, Goyal Trade Center, Sona Cinema, Shantivan, Borivali (E), Mumbai-400 066.

Tel.: 2897 6621 Email: spnatani@gmail.com Web.: www.caspnatani.in